Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Allergan Clear all
Completed No phase listed Observational

Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employees

NCT01162668
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Jackson, Mississippi • Oxford, Mississippi • Pascagoula, Mississippi
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 1, 2026, 10:08 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study

NCT04917731
View directory record Official record
Conditions
Cold Intolerance
Interventions
Botulinum toxin type A
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

NCT04124705
View directory record Official record
Conditions
Hypothyroidism, Thyroid Disease, Euthyroid, Thyroid Gland, Thyroid Hormones
Interventions
Armour® Thyroid, Levothyroxine
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Greenbrae, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 1, 2026, 10:08 PM EDT
Terminated Not applicable Interventional Results available

Botulinum Toxin A for Herpes Labialis

NCT01225341
View directory record Official record
Conditions
Herpes Labialis
Interventions
onabotulinumtoxinA, Bacteriostatic normal saline
Drug · Other
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332059
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bel Air, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

NCT02462486
View directory record Official record
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
73
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Restasis for Treatment of Brittle Nails

NCT00986427
View directory record Official record
Conditions
Brittle Nails
Interventions
Restasis (cyclosporine ophthalmic emulsion) 0.05%, Refresh® Dry Eye therapy
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Results available

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

NCT00735449
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

NCT01157364
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
36
States / cities
Artesia, California • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity

NCT00462449
View directory record Official record
Conditions
Upper Extremity Spasticity, Stroke, Acquired Brain Injury
Interventions
Functional Electrical Stimulation (FES) through the Ness H200
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 1, 2026, 10:08 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Vollure for the Correction of Atrophic Facial Scarring

NCT04519515
View directory record Official record
Conditions
Atrophic Scar
Interventions
Allergan Vollure
Device
Lead sponsor
Siperstein Dermatology
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

NCT00972374
View directory record Official record
Conditions
Rhegmatogenous Macula-off Retinal Detachment
Interventions
400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

NCT00464438
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
gatifloxacin, moxifloxacin 0.5% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
Up to 31 Days
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

NCT01603615
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Pasadena, California • Pomona, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 4 Interventional

A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis

NCT00168415
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 28, 2008 · Synced Sep 1, 2026, 10:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Telemedicine to Improve Spasticity Diagnosis Rates

NCT03211390
View directory record Official record
Conditions
Spasticity, Muscle, Muscular Diseases, Musculoskeletal Disease, Muscle Hypertonia, Muscle Spasticity, Neuromuscular Manifestations, Signs and Symptoms, Nervous System Diseases, Neurologic Manifestations
Interventions
Neurological Examination, Teleneurological Examination
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 1, 2026, 10:08 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

NCT03712137
View directory record Official record
Conditions
Jawline Definition
Interventions
VOLUX XC, No-treatment control
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema

NCT02471651
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

NCT02320149
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sarecycline, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
9 Years to 45 Years
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Beverly Hills, California • Encino, California • La Mesa, California + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 1, 2026, 10:08 PM EDT
Completed No phase listed Observational Results available

Surveillance of Ocular Surface Flora (SURFACE)

NCT00621933
View directory record Official record
Conditions
Cataract
Interventions
Not listed
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 1 Interventional

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

NCT01946568
View directory record Official record
Conditions
Bacterial Infections.
Interventions
Dalbavancin
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
3 Months to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 1, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

NCT04393441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Azusa, California • Glendale, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 1, 2026, 10:08 PM EDT